0
Abstract: Slide Presentations |

LONG-TERM BENEFITS OF SILDENAFIL TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION FREE TO VIEW

Joanna Pepke-Zaba, MD; Martin C. Brown, Other*; Tamiza Parpia, PhD; Claire Gilbert; Gary Burgess, MD
Author and Funding Information

Pfizer Ltd, Sandwich, United Kingdom


Chest


Chest. 2005;128(4_MeetingAbstracts):161S. doi:10.1378/chest.128.4_MeetingAbstracts.161S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Sildenafil inhibits PDE5, enhancing cGMP-mediated relaxation of pulmonary vasculature. We report the effects of 6 months oral sildenafil therapy on health-related quality of life (HR-QoL) in pulmonary arterial hypertension (PAH) patients.

METHODS:  We assessed the HR-QoL effects of sildenafil (20, 40, or 80 mg tid) in a 12-week, double-blind, placebo-controlled study (SUPER-1) and an open-label extension (SUPER-2). Patients recorded their assessment of HR-QoL using SF-36 and EQ-5D questionnaires. Open-label data are presented for patients who received sildenafil for 24 weeks.

RESULTS:  Improvement from baseline to Week 12 was observed in all HR-QoL domains for sildenafil-treated patients, and these benefits were maintained for 24 weeks.

CONCLUSION:  Sildenafil improves HR-QoL of PAH patients, and these improvements appear to be maintained for at least 6 months. Effects are strongest in domains addressing the physical impact of health on daily activities and the patient’s overall perception of health.

CLINICAL IMPLICATIONS:  These patient-reported outcome data demonstrate the benefits of continued sildenafil treatment for PAH.

DISCLOSURE:  Martin Brown, Grant monies (from industry related sources) Actelion, Encysive, Myogen, Pfizer Ltd, United Therapeutics and Schering AG; Employee Papworth Hospital; Consultant fee, speaker bureau, advisory committee, etc. Actelion, Encysive.

Mean (95% CI) change in HR-QoL domains from SUPER-1 baseline, for patients who received placebo or sildenafil for 12 weeks (SUPER-1), and patients who received sildenafil for 24 weeks (SUPER-2)

SUPER-1SUPER-2Placebo (n=70)Sildenafil (n=200)Sildenafil (n=184)SF-36Physical functioning4.5 (0.7, 8.3)13.7*** (11.0, 16.4)16.4 (13.5, 19.2)Role-physical15.4 (5.6, 25.3)19.8 (14.2, 25.3)20.2 (14.0, 26.3)Bodily pain4.9 (0.1, 9.7)7.1 (3.2, 11.1)6.6 (2.6, 10.6)General health0.3 (-3.4, 4.0)8.0*** (5.7, 10.3)7.9 (5.5, 10.3)Vitality5.5 (1.4, 9.6)11.7* (8.5, 14.9)11.4 (7.8, 14.9)Social functioning7.3 (1.4, 13.2)12.9 (9.2, 16.6)13.9 (9.8, 18.0)Role-emotional12.3 (0.9, 23.7)14.7 (8.1, 21.4)17.0 (10.3, 23.6)Mental health5.3 (1.5, 9.2)9.2 (6.3, 12.0)8.9 (5.8, 12.0)EQ-5DCurrent health state0.6 (-3.1, 4.3)7.9** (5.6, 10.2)10.4 (7.9, 13.0)Utility index0.005 (-0.048, 0.059)0.101** (0.065, 0.136)0.079 (0.044, 0.115)

n-numbers varied slightly for each domain due to missing responses

Monday, October 31, 2005

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543